Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study

ConclusionsA switch to ATV/r or DRV/r may result in more rapid reduction in TC and the TC:HDL‐C ratio in PHIV youth, potentially impacting long‐term cardiovascular disease risk.

Source: HIV Medicine - November 21, 2017 Category: Infectious Diseases Authors: J Jao, W Yu, K Patel, TL Miller, B Karalius, ME Geffner, LA DiMeglio, A Mirza, JS Chen, M Silio, EJ McFarland, RB Van Dyke, D Jacobson, Tags: Original Research Source Type: research